C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis

Atherosclerosis

Volumn 158, Issue 2, 2001, Pages 495-498

  Moriarty, Patrick M ^a   Gibson, Cheryl A ^b   Shih, Jessie ^c   Matias, Matthew S ^c  

^a Division of Clinical Pharmacology   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Atherosclerosis; C reactive protein; LDL apheresis

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; HEPARIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; APHERESIS; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEVICE; DISEASE MARKER; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

BLOOD COMPONENT REMOVAL; C-REACTIVE PROTEIN; FEMALE; FIBRINOGEN; HEPARIN; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0034802732     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(01)00633-5     Document Type: Article

References (30)

1. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
2. Role of inflammation in the pathogenesis of unstable coronary artery diseases
3. Activation of human aortic smooth muscle cells is inhibited by PPAR but not by PPAR activators
4. Effects of statins on C-reactive protein in patients with coronary artery disease
5. H.E.L.P. apheresis therapy in the treatment of severe hypercholesterolemia: 10 Years of clinical experience
6. Incorporation of low-density lipoprotein apheresis into the treatment program of patients with severe hypercholesterolemia
7. Effect of apheresis of low-density lipoprotein (LDL) on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease
8. Rapid automated high sensitivity enzyme immunoassay of C-reactive protein
9. Multilayer film elements for clinical analysis
10. Gerinnungsphysiologische Schnell-methode zur bestimmung des fibrinogens
11. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys
12. Treatment of hypercholesterolemia with Heparin-Induced Extracorporeal Low-Density Lipoprotein Precipitation (HELP)
13. Weekly treatment of diet/drug-resistant hypercholesterolemia with the heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) system by selective plasma low-density lipoprotein removal
14. Inflammation markers and coronary heart disease
15. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
16. C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons
17. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease
18. Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation
19. Independent prognostic value of elevated C-reactive protein in unstable angina
20. Enhanced inflammatory response in patients with preinfarction unstable angina
21. Assessment by measuring circulating complement C-reactive protein complexes
22. Direct proinflammatory effect of C-reactive protein on human endothelial cells
23. C-reactive protein in the arterial intima. Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis
24. Effect of single LDL apheresis (H.E.L.P. Method) on the adhesion molecules sVCAM-1, SICAM-1 and P-selectin
25. HELP apheresis in the treatment of sepsis
26. C-reactive protein as a cardiovascular risk factor. More than an epiphenomenon?
27. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: A TIMI 11A substudy
28. Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction